Increased Confidence in Protein Quantitation: Quantitation of Infliximab in Human Serum with LC-MS/MS for Clinical Research

In this webinar, a sensitive, robust and cost-effective method will be presented for the bioanalysis of IFX with LC–MS/MS by means of a target-based pre-analytical sample purification.

The therapeutic monoclonal antibody, Infliximab (IFX), is a widely used drug for the treatment of several inflammatory autoimmune diseases. However, approximately 10% of patients develop anti-infliximab antibodies (ATIs) rendering the treatment ineffective. Early detection of underexposure to unbound IFX would result in a timely switch of therapy, which could aid in the treatment of this disease.

What will you learn?

• How to develop a confident, robust, reliable, and sensitive quantitation assay for proteins
• Ways to increase efficiency in sample preparation
• The ability to optimize LC and MS methods for performing protein quantitation assays with confidence
• How to address critical challenges in a preclinical environment: from achieving sensitivity to reducing cost/sample

Fill out the form to view the free
on-demand webinar

* Required field

To ensure that we are complying with your preferences, we need to confirm your permission to send you communication. Please check the form of communication that you agree for us to contact you: